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Abstract: The development of nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) selective for 
cyclooxygenase (COX)-2 (named coxibs) has been driven by the aim of reducing the incidence 
of serious gastrointestinal (GI) adverse events associated with the administration of traditional 
(t) NSAIDs – mainly dependent on the inhibition of  COX-1 in GI tract and platelets. However, 
their use has unravelled the important protective role of  COX-2 for the cardiovascular (CV) 
system, mainly through the generation of prostacyclin. In a recent nested-case control study, 
we found that patients taking NSAIDs (both coxibs and tNSAIDs) had a 35% increase risk of 
myocardial infarction. The increased incidence of thrombotic events associated with profound 
inhibition of COX-2-dependent prostacyclin by coxibs and tNSAIDs can be mitigated, even 
if not obliterated, by a complete suppression of platelet COX-1 activity. However, most 
tNSAIDs and coxibs are functional COX-2 selective for the platelet (ie, they cause a profound 
suppression of COX-2 associated with insufﬁ  cient inhibition of platelet COX-1 to translate 
into inhibition of platelet function), which explains their shared CV toxicity. The development 
of genetic and biochemical markers will help to identify the responders to NSAIDs or who 
are uniquely susceptible at developing thrombotic or GI events by COX inhibition. We will 
describe possible strategies to reduce the side effects of etoricoxib by using biochemical 
markers of COX inhibition, such as whole blood COX-2 and the assessment of prostacyclin 
biosynthesis in vivo.
Keywords: etoricoxib, nonsteroidal antiinﬂ  ammatory drugs, COX-2, gastrointestinal toxicity, 
cardiovascular toxicity, prostacyclin
Nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) are commonly used in the general 
population for treating pain and inﬂ  ammatory conditions (Burke et al 2006). 
They comprise traditional (t) NSAIDs and NSAIDs selective for cyclooxygenase 
(COX)-2 (named coxibs) which were developed to reduce the risk of serious 
gastrointestinal (GI) complications – dependent, at least in part, on the inhibition 
of COX-1 (FitzGerald and Patrono 2001). The therapeutic effects (analgesic and 
anti-inﬂ  ammatory) of NSAIDs, both traditional and coxibs, are mostly due to the 
inhibition of COX-2-dependent prostanoids (Figure 1A). In placebo-controlled 
randomized clinical trials (RCTs), coxibs (rofecoxib [Vioxx®], celecoxib 
[Celebrex®, Artilog®, Solexa®, Artrid®] and valdecoxib [Bextra®]) were associated 
with an increase in the relative risk (RR) of cardiovascular (CV) events by 1- to 
2.7-fold (Ott et al 2003; Bresalier et al 2005; Solomon et al 2005; Pﬁ  zer 2005; 
Nussmeier et al 2005). However, the results of observational studies and a meta-
analysis of data derived from trials with coxibs have shown that the CV hazard is 
not restricted to NSAIDs selective for COX-2 but also applies to some tNSAIDs, 
such as diclofenac (Hernandez-Diaz et al 2006; Kearney et al 2006). In a recent 
nested-case control study, we found that patients taking NSAIDs (both coxibs Therapeutics and Clinical Risk Management 2008:4(5) 984
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Figure 1 Pathways of prostanoid biosynthesis. (A) Prostanoids (PGE2, PGD2, PGF2α, PGI2,   TXA2) are produced by COX-1 and COX-2 and speciﬁ  c synthases; (B) PGH2, 
generated by cyclooxygenase and peroxydase activity of COX, is then converted to prostanoids by the activity of different synthases.
and tNSAIDs) had a 35% increased risk of myocardial 
infarction (Patrignani et al 2008a). Clinical results suggest 
that the CV hazard associated with the administration 
of NSAIDs is dose-dependent (Patrignani et al 2008a; 
Solomon et al 2008). In addition, the genetic background 
of the individual may play a role in increased susceptibility 
to inhibition of NSAIDs (Arehart et al 2008). To limit the 
possible detrimental effects, associated with the adminis-
tration of this efﬁ  cacious class of drugs, is necessary to 
develop strategies of risk management through the iden-
tiﬁ  cation of genetic and biochemical markers to select the 
responders to NSAIDs or who are uniquely susceptible to 
developing thrombotic or GI events by COX inhibition.
Differential COX pathways
are effective in health and disease
Biology of COX-1 and COX-2
Prostanoids are lipid autacoids – including prostaglandin (PG) 
E2, PGF2α, PGD2, prostacyclin (PGI2), and thromboxane(TX) 
A2 – that are immediately released outside the cell after 
intracellular biosynthesis and modulate a wide variety of Therapeutics and Clinical Risk Management 2008:4(5) 985
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physiologic and pathologic processes via the interaction with 
speciﬁ  c receptors expressed mostly on the surface of target 
cells (Narumiya et al 1999; Breyer et al 2001).
Under normal physiologic conditions, prostanoids play 
an essential homeostatic role in the GI cytoprotection, 
hemostasis, renal physiology, gestation, and parturition (Funk 
2001; Patrono et al 2001; FitzGerald 2003). Moreover, they 
play important roles in pathophysiologic processes such as 
inﬂ  ammation, cancer, and thrombosis (Funk 2001; Patrono 
et al 2001; FitzGerald 2003). Two isoforms of COX (COX-1 
and COX-2) have been cloned and characterized (Simmons 
et al 2004). COX-1 and COX-2 are the products of different 
genes. COX-1 is considered a “housekeeping gene” by virtue 
of constitutive low-levels of expression in most cell types. 
However, high levels of constitutive expression of COX-1 
have been detected in the stomach, platelets, and the kidney. In 
addition, COX-1 can be regulated during development (Rocca 
et al 1999). In contrast, the gene for COX-2 is a primary 
response gene with many regulatory sites; thus, COX-2 
expression can be rapidly induced by bacterial endotoxin 
(LPS), cytokines, such as interleukin (IL)-1β and tumor 
necrosis factor-α, growth factors, and the tumor promoter 
phorbol myristate acetate (PMA) (reviewed by Kang et al 
2007). However, COX-2 is constitutively expressed in some 
cells in lung (Asano et al 1996), brain (Yamagata et al 1993; 
Kaufmann et al 1997), kidney (Harris et al 1994), pancreatic 
β-cells (Robertson 1998), and GI carcinomas (Ristimaki et al 
1997; Shao et al 2000; Carlson et al 2003).
COX-1 and COX-2 share the same catalytic activities: 
the cyclooxygenase which oxidizes arachidonic acid (AA) 
to PGG2 and the peroxidase which reduces PGG2 to the 
unstable endoperoxide PGH2, precursor of prostanoids (Smith 
et al 2000) (Figure 1B). Although the peroxidase reaction is 
considered the second step in the formation of PGH2, the COX 
reaction is absolutely dependent on peroxidase activity for its 
activation (Malkowski et al 2000). However, the two COX-
isozymes require different levels of hydroperoxides to initiate 
cyclooxygenase catalysis, ie, COX-2 requires considerably 
lower levels of hydroperoxides than COX-1 (Kulmacz and 
Wang 1995; Marnett et al 1999). Elegant work performed by 
Funk’s group reveals that COX-1 can partially compensate for 
COX-2 function but that this is limited by the differential abil-
ity of these two isoforms to metabolize low concentrations of 
arachidonate (Yu et al 2007). In fact, COX-2 catalysis occurs at 
lower levels of free AA than COX-1 (Swinney et al 1997).
These differences in the regulation of COX-1 and 
COX-2 catalysis contribute to the development of cell-speciﬁ  c 
pathways of prostanoid biosynthesis dominated by one or the 
other enzyme in vivo even in the presence of the concurrent 
expression of   the 2 isozymes (Capone et al 2007). As an 
example, in endothelial cells where different antioxidant 
defence systems are operative to maintain a reductive cytosolic 
environment, COX-2 is the dominant pathway turned on to 
generate prostacyclin, an important anti-atherogenic and anti-
thrombotic mediator (Grosser et al 2006) (Figure 2).
COX-2 is the major pathway in pain
Other than in inﬂ  ammation and pyresis, COX-2 plays an 
important role in nociception (Vane et al 1998). Noxious 
stimuli (eg, physical, chemical, thermal) in peripheral 
tissues cause damage and the inﬂ  ammatory response leads 
to the release of pain-producing substances that activate 
nociceptors on the terminals of sensory nerve ﬁ  bers. This pain 
is the hallmark of protective response to adverse stimuli and 
subsides with removal of the stimulus. In this context, the 
induction of  COX-2, leading to enhanced prostanoid release, 
translates into sensitization of peripheral nociceptor terminals 
and produces localized pain hypersensitivity. In fact, 
prostanoids increase neuronal activity in nociceptive nerve 
ﬁ  bers by raising cAMP levels and lowering the activation 
threshold for opening of tetrodotoxin-resistant sodium 
channels in the neuronal membrane. PGE2 and prostacyclin, 
produced in the peripheral terminals of sensory nerve 
endings, are hyperalgesic and enhance nociception produced 
by other mediators (such as bradykinin) (Murata et al 1997; 
Nakao et al 2007). Moreover, peripheral inﬂ  ammation also 
generates pain hypersensitivity in neighboring uninjured 
tissue (secondary hyperalgesia), because of increased 
neuronal excitability in the spinal cord (central sensation) and 
a syndrome comprising diffuse muscle and joint pain, fever, 
lethargy, and anorexia (Samad et al 2001). NSAIDs play an 
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Figure 2 Vascular prostacyclin counteracts the cardiovascular effects of platelet 
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antinociceptive action by acting both at peripheral sites and at 
central sites mainly through COX-2 inhibition. Both COX-1 
mRNA and COX-2 mRNA as well as COX-1 and COX-2 
proteins are expressed constitutively in the spinal cord but 
only COX-2 can be induced in response to exogenous and 
endogenous cytokines (Beiche et al 1996; Inoue et al 1999; 
Tonai et al 1999). Like nociceptive pain, hyperalgesia is 
linked to an adverse stimulus and diminishes with healing 
and decreased inflammation. Prolonged acute pain and 
hyperalgesia, however, can evolve into chronic pain.
The results of RCTs showing a comparable pain relief 
by NSAIDs selective for COX-2 and tNSAIDs both in 
acute clinical pain models (for example, oral surgery) and 
chronic clinical pain models (such as osteoarthritis [OA] 
and inﬂ  ammatory arthropaties), support a major role of 
inhibition of COX-2 in their clinical efﬁ  cacy (Fitzgerald 
and Patrono 2001; Sciulli et al 2005). However, it should be 
pointed out that often the RCTs, comparing tNSAIDs and 
coxibs, had inadequate power to detect small differences 
possibly associated with inhibition of COX-1. Mostly, they 
were sized to detect equivalence, not superiority, of either 
(Patrono et al 2001).
COX-1 is the major pathway in GI 
protection
Prostanoids (PGE2 and prostacyclin) are key mediators to 
maintain gastric mucosal blood ﬂ  ow and increase protective 
mucus as well as bicarbonate production (Wilson 1991). 
Several lines of evidence show that prostanoids produced in 
normal GI tissue which are required for normal physiological 
functioning are derived from the COX-1 isoform (Kargman 
et al 1996). However, upregulation of  COX-2 in the margin of 
healing ulcers and evidence from the use of COX inhibitors in 
rodents has raised concerns that COX-2 might be involved in 
the healing of existing ulcers (Shigeta et al 1998; Takahashi 
et al 1998). However, COX-2 up-regulation in the GI tract 
has been observed in cancer development (Romano et al 
1998; Prescott and Fitzpatrick 2000; Nardone et al 2004; 
Wang and Dubois 2006).
COX-1 is involved in TXA2-dependent 
platelet function
Platelets generate TXA2 from AA through the activity 
of COX-1 (Patrignani et al 1999). TXA2 generated in 
response to a variety of stimuli (for example, collagen, 
thrombin, and adenosine diphosphate) participates in the 
control of hemostasis through the induction of irreversible 
platelet aggregation triggered by the interaction with 
G-protein–coupled receptors, the TXA2 receptors (Alfranca 
et al 2006). Recent ﬁ  ndings show that tiny concentrations 
of TXA2 can cause platelet activation (Minuz et al 2002; 
Pulcinelli et al 2005; Minuz et al 2006). Thus, 10 nM of 
the TXA2 mimetic U46619 induces platelet adhesion and 
shape change (Minuz et al 2002), and in the presence of 
a subthreshold concentration of collagen it causes platelet 
aggregation (Pulcinelli et al 2005). Moreover, TXA2 causes 
vasoconstriction and vascular proliferation; thus, it is 
involved in atherogenesis and increase in blood pressure 
(Figure 2) (Grosser et al 2006).
COX-2-dependent prostacyclin
is the major pathway in vascular protection
In vascular endothelial cells, COX-2 plays a dominant role 
in producing important prostanoids to regulate the functions 
of underlying vascular smooth muscle cells and circulating 
cells. Although endothelial cells may generate a different 
array of the prostanoids PGD2, PGE2, and prostacyclin along 
the vascular beds, there is robust evidence that prostacyclin 
is the dominant prostanoid produced in the macrocirculation 
(Moncada et al 1977; Grosser et al 2006).
Prostacyclin potently inhibits aggregation of platelets 
induced by TXA2 and other agonists, vascular smooth 
muscle cell proliferation and vascular tone, leukocyte–endo-
thelial cell interactions, and cholesteryl ester hydrolase 
(Grosser et al 2006). As shown in Figure 2, most of the 
deleterious effects of TXA2 in the CV system are countered 
by prostacyclin, mainly through the activity of COX-2. 
Thus, inhibition of vascular COX-2 leads to loss of the 
protective function associated with prostacyclin. Recently, 
it has been reported an antioxidant role for prostacyclin 
through the induction of hemoxygenase-1 (Egan et al 2004). 
For all these biological actions, prostacyclin has on the 
distinctive features of a cardioprotective mediator. Studies 
in knockout (KO) mice for prostacyclin receptor (IP) and 
the recent ﬁ  ndings of acceleration of CV disease in humans 
by a dysfunctional IP mutation convincingly support the 
protective role of prostacyclin for the CV system (Arehart 
et al 2008; Patrignani et al 2008b).
Biochemical biomarkers of COX 
inhibition
NSAIDs are distinguished on the basis of  their COX-isozyme 
selectivity in vitro, described as the ratio of the concentrations 
required to inhibit the activity of the isozymes by 50% (IC50 
for COX-1/IC50 for COX-2) (Figure 3A). The assessment 
of COX-1/COX-2 ratios in vitro describes an experimental Therapeutics and Clinical Risk Management 2008:4(5) 987
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COX-isozyme selectivity which mirrors the chemical 
features of the different NSAIDs. This is assessed using the 
human whole blood assays which evaluate the effects of 
drugs on platelet COX-1 and monocyte COX-2 activities 
(Patrono et al 1980; Patrignani et al 1994). They are capacity 
indexes of COX-isozyme activities to generate prostanoids 
from endogenous sources of AA and their pharmacological 
inhibition is not influenced by different pathological 
conditions. These assays are based on the measurement of 
PGE2 production, in response to lipopolysaccharide (LPS) 
added to heparinized human blood samples for 24 h which 
reﬂ  ects the time-dependent induction of COX-2 in circulating 
monocytes (Patrignani et al 1994). The parallel measure-
ment of TXB2 production during whole blood clotting is 
used as an index of platelet COX-1 activity (Patrono et al 
1980). When the COX-1/COX-2 IC50 ratio is higher than 1 
the drug is more potent in inhibiting COX-2. When the ratio 
is approximately 1, the drug is a non-selective inhibitor of 
both COX-1 and COX-2. When the ratio is lower than 1, the 
drug is more potent towards COX-1. We assessed COX-1/
COX-2 IC50 values of several COX inhibitors. Interestingly, 
we have found that the biochemical selectivity is a continuous 
variable preventing the separation of tNSAIDs from coxibs 
(Patrignani et al 2008c). However, we can identify some 
drugs more selective for COX-1 than COX-2 (such as aspirin, 
naproxen and ibuprofen) from the wide cluster of agents more 
selective for COX-2 than COX-1. This includes: i) piroxicam 
and indomethacin which are approximately 3-fold more 
selective for COX-2; ii) etodolac, meloxican, diclofenac, 
celecoxib, and valdecoxib which are 6- to 60-fold more selec-
tive for COX-2; iii) the highly selective COX-2 inhibitors 
such as, etoricoxib, rofecoxib, and lumiracoxib which have 
a COX-1/COX-2 IC50 ratio higher than 100 (Table 1).
The whole blood assays also enable estimation of 
achieved COX-isozyme selectivity in humans, which is the 
ratio of isozyme inhibition at a given plasma concentration 
(Figure 3B). Importantly, achieved selectivity of NSAIDs 
varies as a consequence of the dose administered.
There is evidence that the whole blood assays for COX-2 
and COX-1 may be candidate surrogate end-points of efﬁ  cacy 
and GI toxicity of NSAIDs, respectively. It has been shown 
that COX-2 inhibition, as determined by PGE2 levels in 
LPS-stimulated whole blood, can be used as a marker to 
predict drug efﬁ  cacy in humans (Huntjens et al 2005). In fact, 
IC80 (concentration required to inhibit the activity of  COX-2 
by 80% in vitro) values have been found to correlate directly 
with the analgesic/anti-inﬂ  ammatory plasma concentrations 
of different COX inhibitors (Huntjens et al 2005). Thus, 
COX-2 inhibition, by assessing PGE2 levels in the whole 
blood assay in vitro and ex vivo, can be used as a marker to 
predict drug effects (analgesia, antiinﬂ  ammatory effects) in 
humans. Similarly, platelet COX-1 inhibition, by assessing 
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TXB2 levels in the whole blood assay in vitro and ex vivo, can 
be used as a marker to predict toxicity or efﬁ  cacy (GI toxicity 
or antiplatelet effects) in humans by NSAIDs. In fact, Cryer 
and Feldman (1998) reported that the inhibitory effects of 
tNSAIDs on gastric PGE2 synthesis correlate with COX-1 
inhibitory potency in clotting blood.
Now it is critical to establish the CV safety proﬁ  le of 
speciﬁ  c individual NSAIDs, be it tNSAIDs or coxibs, and to 
ﬁ  nd valid surrogate biochemical predictors of that risk.
Studies of clinical pharmacology have shown discordant 
functional implications of inhibition of COX-1 and 
COX-2. A linear relationship exists between the extent 
of inhibition of COX-2 and that of prostacyclin in 
vivo (Patrignani et al 2008a). In contrast, inhibition of 
TXA2-dependent platelet function in vivo occurs when platelet 
COX-1-dependent capacity to synthesize TXA2 (as assessed 
by measuring serum TXB2 levels) is reduced 95% (Reilly 
and FitzGerald 1987). In fact, a non-linear relationship of 
inhibition of platelet TXA2 generation with inhibition of 
TXA2-mediated platelet aggregation has been found (Sciulli 
et al 2006). This is explained by the fact that even tiny 
concentrations of TXA2 may activate the platelets. Minuz 
et al (2006) have shown that low concentrations of TXA2 
activate the tyrosine-kinase-based signaling pathway which 
may translate into a full platelet activation in the presence 
of weak platelet agonists or subthreshold concentrations of 
stronger agonists.
These findings lead to the concept of functional 
COX-2 selectivity by NSAIDs, ie, inhibition of COX-2 in 
the presence of an insufﬁ  cient reduction of platelet COX-1 
activity to translate into inhibition of platelet function. It 
has to be pointed out that most NSAIDs are functionally 
selective for COX-2 at therapeutic doses similarly to coxibs. 
The only tNSAID that has been shown to be functionally 
non-selective for the platelet is naproxen at high doses, in 
some individuals (Capone et al 2004). This depends on the 
fact that naproxen usually administered at high doses bid is 
more potent for COX-1 than COX-2, and it is characterized 
by a pharmacokinetic half-life of approx 14 h (Burke et al 
2006). Thus, naproxen is associated with profound inhibi-
tion of prostacyclin but the possible CV hazard associated 
with this effect may be mitigated by a parallel profound and 
persistent suppression of platelet TXA2 (Capone et al 2004), 
which translates into a small CV protection or neutral effect 
(Hernández-Díaz et al 2006; Kearney et al 2006).
Recent ﬁ  ndings suggest that for functional non-selective 
NSAIDs the extent of inhibition of COX-2-dependent pros-
tacyclin may predict the increased incidence of myocardial 
infarction (MI) (Patrignani et al 2008a). Individual NSAIDs 
with a degree of COX-2 inhibition 90% at therapeutic 
concentrations presented a RR of 1.18 (95% CI, 1.02–1.38) 
while those with a greater COX-2 inhibition had a RR of 
1.60 (95% CI, 1.41–1.81).
Thus, it has been proposed that the assessment of 
whole blood COX-2 ex vivo – alone or in combination 
with the measurement of urinary levels of 2,3-dinor-6-
keto-PGF1α [a biomarker of prostacyclin biosynthesis in 
vivo (Figure 4)] – in association with genetic biomarkers 
(such as polymorphisms in the prostacyclin receptor IP) 
(Arehart et al 2008) may be surrogate end-points of CV 
hazard by pharmacological inhibition of COX-2 (Patrignani 
et al 2008b).
Etoricoxib
Pharmacology
The NSAID selective for COX-2 etoricoxib, 5-chloro-
6’-methyl-3-[4-(methylsulfonyl) phenyl]-2,3’-bipyridine 
(Figure 5) (Riendeau et al 2001) (Arcoxia®, Tauxib®, Algix®) 
has been approved in Europe, Latin America, and Asia-
Paciﬁ  c region for the treatment of OA, rheumatoid arthritis 
(RA), ankylosing spondylitis, acute gouty arthritis, acute 
pain, and chronic musculoskeletal pain, at doses ranging 
between 60 and 120 mg daily depending on the different 
indications.
As shown in Figure 6A, etoricoxib is 162-fold more 
potent towards COX-2 than COX-1 in the whole blood assay 
in vitro. The pharmacokinetics features of etoricoxib are 
reported in Figure 6C (Agrawal et al 2003). Importantly, it 
has a long half-life of 22 h and is metabolized via 6’-methyl 
hydroxylation in human liver microsomes. The reaction is 
Table 1 Biochemical selectivity, assessed as COX-1/COX-2 IC50 values 
of several COX inhibitors (derived from Patrignani et al 2008a)
COX-inhibitors COX-1/COX-2  IC50 values
naproxen 0.49
ibuprofen 0.56
indomethacin 2.9
piroxicam 3.1
etodolac 5.6
meloxicam 13.8
diclofenac 24.4
celecoxib 32
valdecoxib 61a
etoricoxib 162
rofecoxib 255
lumiracoxib 400b
aCOX-1/COX-2 IC50 ratio value from Capone et al 2008.
bCOX-1/COX-2 IC50 ratio value from Patrignani et al 2004.Therapeutics and Clinical Risk Management 2008:4(5) 989
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catalyzed by a number of P450 forms, although CYP3A4 
accounts for the majority (40%–90%) of the activity. 
The remainder of the activity is equally divided between a 
number of other P450s (eg, CYP2D6, CYP2C9, CYP1A2, 
and possibly CYP2C19). In this regard, the P450 reaction 
phenotype of etoricoxib is unique and differs from that of 
other COX inhibitors (Kassahun et al 2001).
As shown in Figure 6B, etoricoxib administered up 
to 120 mg is a selective COX-2 inhibitor. This result has 
been obtained by the extrapolation of COX-1 and COX-2 
inhibition in vitro in the human whole blood assays by the 
maximal plasma concentration achieved after the administra-
tion of etoricoxib at single doses of 5, 10, 20, 40, 120 mg. 
Interestingly, an inhibition of COX-2 by 80% may be reached 
after the administration of 40 mg, suggesting that the dosage 
of the drug could be reduced without affecting efﬁ  cacy.
We performed studies of clinical pharmacology to assess 
achieved COX-2 selectivity ex vivo by the chronic adminis-
tration of etoricoxib 90 mg daily versus the tNSAIDs diclof-
enac 75 mg bid, naproxen 500 mg bid, and aspirin 100 mg 
daily (Figure 7 A–C). As shown in Figure 7A the administra-
tion of etoricoxib (at 12 h after dosing), diclofenac (at 4 h after 
dosing), naproxen (at 12 h after dosing), and low-dose aspirin 
(at 24 h after dosing) caused a median inhibition of COX-1 
of 1%, 60%, 95%, and 98%, respectively. These results show 
that inhibition of platelet COX-1 95% (which translates into 
inhibition of platelet function) occurs in all subjected treated 
with low-dose aspirin and in some of those treated with high-
dose naproxen, at the interval between doses, sustaining an 
anti-platelet effect of high-dose naproxen. In contrast, in all 
subjects treated with diclofenac and etoricoxib, the degree 
of inhibition of platelet COX-1 was not adequate to affect 
signiﬁ  cantly TXA2-dependent platelet function. However, 
our results showed a marked inter-subject variability in 
the inhibition of platelet COX-1 after the administration 
of diclofenac (range 8–98%) and to a lesser extent also 
for etoricoxib (range 0%–48%). As shown in Figure 7B, 
whole blood COX-2 was profoundly affected by etoricoxib, 
diclofenac, and naproxen, but not by low-dose aspirin 
(median inhibition and range: 86% [70–90], 98% [58–100], 
79% [30–83], and 0% [0–31], respectively]. These data 
show that both diclofenac and etoricoxib were administered 
at supratherapeutic doses, in fact most of individuals had a 
COX-2 inhibition higher than 80%, considered sufﬁ  cient to 
translate into efﬁ  cacy. From these values we calculated the 
achieved selectivity (ie the ratio of COX-2 inhibition and 
COX-1 inhibition ex vivo). As shown in Figure 7C, for etori-
coxib and diclofenac the individual values of achieved COX 
selectivity were placed above 1 (which represents a balanced 
inhibition of COX-2 and COX-1) showing that circulating 
concentrations of the two drugs caused a more profound 
inhibition of COX-2 than COX-1. In contrast, naproxen and 
aspirin caused a more profound inhibition of COX-1 than 
COX-2; in fact the ratio of COX-2 /COX-1 inhibition ex 
vivo was always lower than 1. These data clearly show that 
diclofenac and naproxen, despite being considered tNSAIDs, 
are signiﬁ  cantly different in selectivity compared with COX-
isozymes at therapeutic doses. Interestingly, the achieved 
selectivity was not different, in a statistically signiﬁ  cant 
fashion, between etoricoxib and diclofenac. These results 
will be relevant for interpretation of the clinical results, for 
both efﬁ  cacy and toxicity.
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Figure 4 Biosynthesis and metabolism of prostacyclin (PGI2) and thromboxane 
(TX) A2.
Abbreviations: PGIS, prostacyclin synthase;   TXS,   TX synthase.
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Prostanoids are autocoids that act in the proximity 
of the cell where they are generated. In fact, they are 
subjected to an intense metabolism which leads to inac-
tivation of   prostanoids. It proceeds through β-oxida-
tion ω-oxidation, 15-hydroxy dehydrogenation, and 
double-bond reduction through enzymatic pathways in 
liver, kidney, and lung (Ramwell et al 1980; Roberts 
1987) (Figure 4). The assessment of major enzymatic 
metabolites of prostanoids represents an index of their 
systemic biosynthesis. Several lines of evidence sup-
port a dominant platelet origin (mostly COX-1-derived) 
of a major urinary enzymatic metabolite of   TXB2, ie 
11-dehydro-TXB2, while vasculature (mostly COX-2 
derived) represents the dominant origin of a major urinary 
enzymatic metabolite of prostacyclin, ie, 2,3-dinor-6-keto-
PGF1α (Capone et al 2007).
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In susceptible patients, inhibition of prostanoid generation 
by tNSAIDs and coxibs causes sodium retention with 
resulting edema and hypertension (Grosser et al 2006). 
Similarly to thrombogenesis, COX-1 inhibition may 
mitigate the consequence of COX-2 inhibition in the 
kidney. This is compatible with a COX-2-dependent source 
of vasodilatory prostacyclin and COX-1-dependent origin 
of vasoconstrictors, like TXA2 in the kidney (Qi et al 2002; 
Grosser et al 2006). We studied the impact of etoricoxib and 
naproxen on renal and systemic prostanoid biosynthesis by 
assessing 6-keto-PGF1α/TXB2 inhibition ratio and 2,3-dinor-6-
keto-PGF1α/11-dehydro-TXB2 inhibition ratio, respectively, 
after the administration of the drugs (Figure 8).
As shown in Figure 8 A and B, etoricoxib caused a more 
profound inhibition of COX-2 than COX-1 both at renal 
and extrarenal sites. This is predictive of a CV hazard but 
of reduced GI toxicity by etoricoxib. In contrast, naproxen 
reduced more profoundly COX-1 both at renal and extrarenal 
sites (Figure 8A and B), which may translate into reduced 
CV but higher GI side effects.
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Etoricoxib and GI toxicity
The GI safety of etoricoxib has been assessed in the MEDAL 
(Multinational Etoricoxib vs Diclofenac Arthritis Long Term) 
Programme (Laine et al 2007). It was prospectively designed 
to pool data from 3 randomized, double-blind clinical trials: 
the MEDAL study, the Etoricoxib vs Diclofenac Sodium 
Gastrointestinal Tolerability and Effectiveness (EDGE) study, 
and the EDGE II study. Patients with OA or RA aged 50 years 
or over were eligible for enrollment if they had a clinical 
diagnosis of OA of the knee, hip, hand, or spine, or a clinical 
diagnosis of RA that satisﬁ  ed at least 4 of 7 of the American 
Rheumatism Association 1987 revised criteria (Arnett et al 
1988), and in the judgment of the investigator, would require 
chronic therapy with an NSAID. Thus, etoricoxib (60 or 
90 mg daily) and diclofenac (150 mg daily) were compared 
in 34,701 patients with OA or RA for upper GI clinical events 
(bleeding, perforation, obstruction, or ulcer) and the subset of 
complicated events (perforation, obstruction, witnessed ulcer 
bleeding, or signiﬁ  cant bleeding). As shown in Table 2, there 
were signiﬁ  cantly fewer upper GI clinical events with the 
COX-2 selective inhibitor etoricoxib than with the tNSAID 
diclofenac due to a decrease in uncomplicated events, but 
not in the more serious complicated events. Less inhibition 
of gastric COX-1 by etoricoxib than diclofenac (etoricoxib is 
a more COX-2 selective drug than diclofenac in vitro and ex 
vivo [Patrignani et al 1997; Tacconelli et al 2002] [Figure 7]) 
may explain the reduced incidence of uncomplicated GI 
events. In contrast, the comparable rates of GI bleeding by 
the two drugs could be due to a similar impact on platelet 
COX-1, in some individuals, and on healing of gastric lesions. 
In fact, it has been shown that COX-2 plays an important 
role in the healing of gastric ulcers and that inhibition of 
COX-2 delays ulcer healing (Konturek et al 2005). As shown 
in Figure 7B, etoricoxib and diclofenac have a comparable 
profound impact on COX-2 (80%).
In MEDAL, the use of low-dose aspirin and proton pump 
inhibitors (PPIs) was allowed. Analyzing the data in aspirin 
and non-aspirin populations, it has been found that etoricoxib 
reduced the risk of uncomplicated upper GI events compared 
with diclofenac in patients taking low-dose aspirin regularly, 
but the magnitude of the GI beneﬁ  t decreased with low-dose-
aspirin use (aspirin: hazard ratio 0.73, 95% CI 0.64–1.07 
versus no-aspirin: 0.52, 0.38–0.71, p = 0.021) (Laine et al 
2007). PPIs were used concomitantly for at least 75% of the 
study period by 40% of patients and treatment effects did 
not differ signiﬁ  cantly in these individuals; however, signiﬁ  -
cantly fewer patients discontinued etoricoxib than diclofenac 
due to dyspepsia, and this decrease was similar in patients 
who took PPIs, suggesting that the COX-2-selective inhibitor 
provided symptomatic beneﬁ  t even in patients already taking 
a PPI (Laine et al 2007).
Etoricoxib and CV toxicity
In placebo-controlled RCTs, coxibs (rofecoxib, celecoxib, 
and valdecoxib) were associated with increased RR of CV 
events (1.92–3.7) (Ott et al 2003; Bresalier et al 2005; 
Nussmeier et al 2005; Pﬁ  zer 2005; Solomon et al 2005). An 
overview of data derived from trials with coxibs suggests 
that MI predominates over stroke (Kearney et al 2006). 
These results led the regulatory authorities such as the 
Food and Drug Administration (FDA) and the European 
Agency for the Evaluation of Medicinal Products (EMEA) 
to restrict the use of these drugs (Patrignani et al 2008c). 
However, the results of observational studies and a meta-
analysis of data derived from trials with coxibs have shown 
that the CV hazard is also associated with some tNSAIDs, 
such as diclofenac (Hernandez-Diaz et al 2006; Kearney 
et al 2006). A plausible mechanism in increased risk of 
vascular events in individuals treated with NSAIDs selec-
tive for COX-2 and some tNSAIDs is the inhibition of 
COX-2-dependent prostacyclin unaccompanied by inhibition 
of COX-1-dependent TXA2 at functional range, ie 95%. 
In fact, most tNSAIDs are as COX-2 selective as coxibs for 
platelet function. In addition, coxibs and tNSAIDs inhibit 
profoundly prostacyclin generation in vivo, as assessed by 
the measurement of urinary levels of a major enzymatic 
metabolite 2,3-dinor-6-keto-PGF1α (Catella-Lawson et al 
1999; McAdam et al 1999).
Table 2 Risk of GI events with etoricoxib and diclofenac in MEDAL study (derived from Laine et al 2007)
Type of GI events Hazard ratio with 
etoricoxib vs diclofenac
95% CI p
All upper-GI events 0.69 0.57–0.83 0.0001
Uncomplicated upper-GI events 0.57 0.45–0.74 0.0001
complicated upper-GI events 0.91 0.67–1.24 0.0001
Abbreviations: GI, gastrointestinal; MEDAL, Multinational Etoricoxib vs Diclofenac Arthritis Long Term.Therapeutics and Clinical Risk Management 2008:4(5) 994
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The CV hazard associated with the use of coxibs led to 
the voluntarily withdrawal from the US and EU market of 
rofecoxib and valdecoxib, in 2004 and 2005, respectively. 
Recently, the FDA has formally rejected manufacturer 
application for approval of etoricoxib as a prescription pain 
reliever. The FDA decision was inﬂ  uenced by the results of 
safety analyses from the MEDAL Program (Cannon et al 
2006). The authors reported that etoricoxib (60 or 90 mg 
daily, mean duration of therapy was 18 months) and diclof-
enac (150 mg daily, ie 50 mg tid or 75 mg bid) administered 
to OA or RA patients have comparable rates, constant 
over time, of thrombotic CV events (Cannon et al 2006). 
Despite etoricoxib and diclofenac having different COX-2 
selectivity in vitro, they are functional COX-2 selective for 
platelet function. The shared pharmacodynamic translates 
into comparable incidence of thrombotic events detected 
in MEDAL.
Aside from the platelet, the relationship between 
inhibition of prostaglandin formation and prostaglandin 
dependent function appears to be roughly linear in other 
cell types. In this context, even an incomplete inhibition of 
COX-1 might attenuate the functional effect derived from 
inhibition of COX-2-dependent prostacyclin. This may occur 
in the kidney where COX-2 is the source of vasodilatory 
prostacyclin and COX-1 is the source of vasoconstrictor 
TXA2 (Qi et al 2002; Grosser et al 2006). This is sustained 
by the results of MEDAL where the selective COX-2 inhibi-
tor etoricoxib caused a higher incidence of blood pressure 
than the less selective tNSAID diclofenac. However, the 
more pronounced signal from MI rather than stroke showed 
by the use of NSAIDs (traditional and selective for COX-2) 
suggests that thrombosis is the dominant component of the 
CV hazard and thus lesser degrees of selectivity are likely 
only to mitigate the hazard to a marginal extent.
Both EMEA and FDA and the American Heart Associa-
tion (Antman et al 2007) issued the recommendations that 
selective COX-2 inhibitors are contraindicated in patients 
with ischemic heart disease and/or stroke, that they have to 
be avoided in patients with risk factors for coronary heart 
disease, and that all patients have to take the lowest effective 
dose for the shortest time necessary to control symptoms. 
Importantly, we have recently shown that the degree of 
COX-2 inhibition achieved by individual NSAIDs (an index 
of drug potency/exposure), that do not show functional 
suppression of platelet COX-1, is a determinant of the CV 
hazard associated with them (Patrignani et al 2008a, c).
Thus, a possible approach to reduce the CV risk 
associated with etoricoxib will be to use the lowest effective 
dose. Studies of efﬁ  cacy with lower doses of etoricoxib than 
those used in MEDAL seem to support this possible strategy. 
Etoricoxib 30 mg/day has been shown efﬁ  cacious in OA 
compared with either ibuprofen 800 mg tid (Wiesenhutter 
et al 2005) or diclofenac 50 mg tid (Leung et al 2002). More-
over, it has been recently assessed the efﬁ  cacy of etoricoxib 
30 mg daily versus the recommended therapeutic dose of 
celecoxib, 200 mg daily, in the treatment of OA patients 
(Bingham et al 2007). The primary hypothesis was that 
etoricoxib 30 mg would be at least as effective as celecoxib 
200 mg for Western Ontario and McMaster (WOMAC) 
Pain Subscale, WOMAC Physical Function Subscale and 
Patient Global Assessment of Disease Status. Etoricoxib was 
non-inferior to celecoxib and both were superior to placebo 
(p  0.001) for all three outcomes. The authors suggested 
that etoricoxib 30 mg was at least as effective as celecoxib 
200 mg and had similar safety in the treatment of OA of knee 
and hip. As shown in Figure 6B, etoricoxib 30 mg seems 
adequate to reduce whole blood COX-2 at a degree appro-
priate to translate into clinical efﬁ  cacy. However, further 
studies of clinical pharmacology in patients with OA and 
RA should be performed to verify the impact of etoricoxib 
30 mg on biochemical markers of COX inhibition, such as 
whole blood COX-2 and systemic and renal biosynthesis of 
prostacyclin and TXA2.
Conclusions
NSAIDs are an important and efﬁ  cacious class of drugs 
for the management of musculoskeletal symptoms. The 
development of NSAIDs selective for COX-2 – to reduce 
the incidence of serious GI adverse effects compared with 
tNSAIDs mainly dependent on the inhibition of COX-1 
in GI tract and platelets – has unravelled the important 
protective role of COX-2 for the CV system, mainly 
through the generation of prostacyclin. In a recent nested-
case control study, we found that patients taking NSAIDs 
(both coxibs and tNSAIDs) had a 35% increase risk of MI. 
The increased incidence of thrombotic events associated 
with profound inhibition of COX-2-dependent prostacyclin 
can be mitigated, even if not removed, by a complete 
suppression of platelet COX-1 activity. In fact, inhibition 
of TXA2-dependent platelet function occurs when platelet 
COX-1 activity, assessed ex vivo, is reduced 95% (Reilly 
and FitzGerald 1987). We have introduced the concept of 
functional COX-2 selectivity (ie, a profound suppression 
of COX-2 associated with insufﬁ  cient inhibition of platelet 
COX-1 to cause inhibition of platelet function) which is 
a feature shared by most tNSAIDs and coxibs. We have Therapeutics and Clinical Risk Management 2008:4(5) 995
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recently shown that inhibition of COX-2 and the functional 
selectivity with which it is achieved is relevant to CV 
hazard from NSAIDs and relates to drug potency (exposure) 
(Patrignani et al 2008a, c).
The development of genetic and biochemical markers 
will help to identify the responders to NSAIDs or who 
are uniquely susceptible at developing thrombotic or GI 
events by COX inhibition. This will lead to the develop-
ment of individual responder approaches. We propose that 
the assessment of whole blood COX-2 ex vivo (alone or 
in combination with urinary 2,3-dinor-6-keto-PGF1α) may 
represent a valid surrogate end-point to predict CV risk for 
functionally selective COX-2 inhibitors. The use of these 
biochemical markers together with genetic biomarkers will 
help to select patients uniquely susceptible to developing CV 
risk through inhibition of COX-2-dependent-prostacyclin 
when exposed to NSAIDs. Their use can lead to a rational 
selection of doses for efficacy and will help to make 
decisions in risk management of tNSAIDs and NSAIDs 
selective for COX-2.
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